TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04346784

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Positive placebo ABMT
Description: Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes
Study: NCT00601913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Study: NCT04067609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: subjects will receive a single administration of either 0.1 mg/kg of intravenous dexamethasone in 90mL of normal saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100mL of normal saline (placebo)
Study: NCT01929161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 24 International Units

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: 24 International Units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 24 International Units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for oxytocin)
Description: intranasal spray manufactured to mimic oxytocin nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for oxytocin)
Description: intranasal spray manufactured to mimic oxytocin nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for oxytocin)
Description: intranasal spray manufactured to mimic oxytocin nasal spray

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lovingkindness Meditation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lovingkindness Meditation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lovingkindness Meditation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness Meditation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness Meditation
Study: NCT01229176

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-CRM197 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-CRM197 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-CRM197 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-CRM197 vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi Polysaccharide (PS) vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi Polysaccharide (PS) vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine
Study: NCT00601913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study: NCT03897894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Friendly Space
Description: Child Friendly Spaces (CFS) are one of the most widely used interventions to provide Mental Health and Psychosocial Support (MHPSS) as well as provide a protective environment for children in humanitarian settings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Friendly Space
Description: Child Friendly Spaces (CFS) are one of the most widely used interventions to provide Mental Health and Psychosocial Support (MHPSS) as well as provide a protective environment for children in humanitarian settings.
Study: NCT04744012

Intervention type: PROCEDURE
Intervention: Modified Periostal Pocket Flap Technique
Description: After local anesthesia, a full thickness flap was elevated from the lingual wall and a partial thickness flap was performed in the buccal one. After that, the buccal periosteum was detached and dental implants were placed following the biological drilling protocol, getting autologous bone particles from the implant site.~Patient's blood collection was performed and the plasm obtained was poured down on a sterile container and mixed with autologous bone particles collected previously during the drilling procedure. Finally the graft was placed in the pocket prepared previously and the surgical wound was sutured in two planes.
Study: NCT00123266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: 2 mg/kg, IA over 75 mins
Study: NCT00722202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ERB-257

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00748709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 (Afatinib)
Description: BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation
Study: NCT00739180

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Standard care control (no exercise)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Supervised resistance exercise using stack weight equipments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Supervised aerobic exercise using treadmills, bikes, and ellipticals
Study: NCT02864251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days
Study: NCT01669018

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar plexus block using LUT technique
Description: Lumbar plexus block guided by ultrasound and nerve stimulation with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse processes of L3 and L4 until an appropriate neuromuscular response is produced.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar plexus block using SSPS technique
Description: Lumbar plexus block guided by ultrasound and loss of resistance (LOR) with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse process of L5 and the sacral bone until an appropriate LOR is produced.
Study: NCT01247935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: Patients are monitored for pain and discomfort
Study: NCT03322501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Advice, Framed Messaging
Description: The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
Study: NCT04333602

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urinary culture and treatment if asymptomatic bacteriuria is detected
Description: Urinary culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. Based in the assigned group If we detect asymptomatic bacteriuria specific treatment will be instituted or No treatment.
Study: NCT03009643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Patients are treated with iNO for 3-5 days.The concentration of inhaled Nitric Oxide is around 5-10ppm.
Study: NCT01229176

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine
Study: NCT02729246

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Gastric Bypass
Study: NCT00708266

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Openflow microperfusion catheter
Description: Macro-perforated, double lumen catheter used to withdraw interstitial fluid samples from different tissues.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Openflow microperfusion catheter
Description: Macro-perforated, double lumen catheter used to withdraw interstitial fluid samples from different tissues.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intralipid 20%
Description: Lipid emulsion used in clinical practice as supplementary intravenous nutrition. 28 hours venous infusion during the treatment study visits.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline Solution
Description: 0.9% sodium chloride solution, used in clinical practice for venous hydration. 28 hours infusion during the control study visits.
Study: NCT02725372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide 75 mcg/kg IBW/hr
Description: Inhaled Nitric Oxide 15mcg/Kg IBW/hr for two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period (Week 3 to Week 18)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1 Placebo arm: Inhaled Nitric Oxide 15mcg/Kg IBW/hrfor two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period
Study: NCT01240590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crolibulin
Description: Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crolibulin
Description: Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crolibulin
Description: Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crolibulin
Description: Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)
Study: NCT02467985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIGARO
Description: flow of insufflation set to 2-3L / min. Once the intervention is complete, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed with or without fascial closure according to the standard display. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. A suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who apply 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 seconds. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures. The patient will be given to neutral at the end of the procedure.
Study: NCT00860457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV infusion Day 1 of each 28-day cycle for maximum of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 IV Days 1-5 of each 28-day cycle for maximum of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5-10 mg PO daily on Days 1-21 of each 28-day cycle for a maximum of 6 cycles
Study: NCT01583959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid tablets 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid tablets 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matched placebo to folic acid 5 mg tables, to be given for 4 days a week
Study: NCT00651326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bicalutamide
Study: NCT03000478

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Study: NCT00273689

Intervention type: DRUG
Group type: OTHER
Intervention: montelukast vs pretreatment with albuterol
Description: montelukast 5 or 10 mg once daily for 3 days vs albuterol 2 puffs, 15 minutes before exercise
Study: NCT03009643

Intervention type: DEVICE
Group type: OTHER
Intervention: lung protective mechanical ventilation
Description: Mechanical ventilation in the SIMV mode (ventilators Evita 2 or 4,Dräger, Lübeck, Germany) with VT 6-8ml/kg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung protective mechanical ventilation
Description: Mechanical ventilation in the SIMV mode (ventilators Evita 2 or 4,Dräger, Lübeck, Germany) with VT 6-8ml/kg

Intervention type: DEVICE
Group type: OTHER
Intervention: Hemodynamic monitoring
Description: Flotrac/Vigileo (Edwards Lifesciences) are used to guide the fluid management.
Study: NCT00273689

Intervention type: DRUG
Group type: OTHER
Intervention: montelukast
Description: Montelukast 5 or 10 mg once daily for 3 days vs Albuterol inhlare 2 puffs, 15 minutes before exercise
Study: NCT04357548

Intervention type: DEVICE
Intervention: FEEDBACK
Description: Once the sample was selected, a test was performed in which the professionals performed 2 minutes of CPR on the dummy without any feedback system, after 5 minutes they performed 2 minutes of CPR with feedback system through the Zoll® monitor with CPR patch -D padz training, to later compare the pretest-posttest results.
Study: NCT00553176

Intervention type: OTHER
Intervention: No intervention
Description: At six-month intervals (January and July), physicians will document disease characteristics, changes in Crohn's therapy, disease progression, key events, the use of ancillary services, and hospitalizations
Study: NCT00611260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vipassana Meditation practice and instruction
Description: 2-3 instructed meditation sessions per week in addition to standard medical care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care
Description: Standard medical care for patients with congestive heart failure plus implanted cardiac defibrillators.
Study: NCT06632574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel cationic liposomes
Description: Paclitaxel cationic liposomes is a modified new drug. In this study, administration is performed through arterial catheter infusion.
Study: NCT04980989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile software for follow-up of early breast cancer
Description: The patients were randomized to use mobile software or telephone calls as the follow-up modality for early breast cancer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile software for follow-up of early breast cancer
Description: The patients were randomized to use mobile software or telephone calls as the follow-up modality for early breast cancer
Study: NCT02535793

Intervention type: OTHER
Group type: OTHER
Intervention: blood test (four dry tubes 7ml) and prick tests
Study: NCT00143390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: take orally one tablet per day of exemestane 25 mg and one tablet per day of anastrozole placebo daily after meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: take orally one tablet of anastrozole 1 mg and one tablet of exemestane placebo daily after meal
Study: NCT02889523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tablets 200 mg, to be administrated per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tablets 200 mg, to be administrated per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m²/dose, D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m²/dose, D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m²/dose, D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m²/dose, D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m²/dose (max 2 mg), D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m²/dose (max 2 mg), D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m²/dose, D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m²/dose, D1
Study: NCT03009643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodynamic monitoring
Description: Flotrac/Vigileo (Edwards Lifesciences) are used to guide the fluid management.
Study: NCT00758121

Intervention type: DEVICE
Intervention: Cardiac Resynchronization Therapy Defibrillator
Description: CRT-D observational study
Study: NCT03303898

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: sampling of 7 blood tubes

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: sampling of 7 blood tubes
Study: NCT00886119

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lens
Description: Silicone hydrogel, soft, multifocal contact lens for daily wear use

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lens
Description: Silicone hydrogel, soft, multifocal contact lens for daily wear use

Intervention type: DEVICE
Group type: OTHER
Intervention: Omafilcon A multifocal contact lens
Description: Hydrogel, soft, multifocal contact lens for daily wear use

Intervention type: DEVICE
Group type: OTHER
Intervention: Omafilcon A multifocal contact lens
Description: Hydrogel, soft, multifocal contact lens for daily wear use
Study: NCT03854890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Indocyanine Green will be injected to the submucosal layer around the lesion one day before surgery.
Study: NCT04900948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Description: Patients received pimecrolimus cream 1% 2 times a day for 3 months. Then use in a double application mode (morning / evening) 3 times a week for up to 1 year of age. Also, patients used emollients 1-2 times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cream 0.1% methylprednisolone aceponate
Description: Patients received 0.1% methylprednisolone aceponate cream 2 times a week for 3 months, and then used for exacerbation of atopic dermatitis. Also, patients used emollients 1-2 times a day.
Study: NCT01503996

Intervention type: BEHAVIORAL
Intervention: alter drinking habits
Description: if dehydration is apparent, more fluid intake is recommended
Study: NCT02889523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 40 mg/m2 in the morning D1 to D5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 40 mg/m2 in the morning D1 to D5
Study: NCT02468856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: Armodafinil 250 mg tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Area under the plasma concentration versus time curve (AUC), Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for armodafinil)
Description: Placebo tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
Study: NCT01739699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT04625491

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT02827695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMASK
Description: Medication adherence and BP monitoring

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EnhancedSC
Description: Standard care without med reminder functions with healthy lifestyle texts
Study: NCT04236882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Attend focus group
Study: NCT03002623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUDC-907
Description: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day 5 days on and 2 days off.